BRAF and melanoma: The European Society for Medical Oncology recommends the use of immunotherapy in unresectable melanoma regardless of the BRAF mutation status, as long as the immunotherapy can be safely administered, meaning that melanoma is not progressing very quickly and there is no imminent threat to any function or organ [6].